Biosite pushes on with sepsis test:
This article was originally published in Clinica
Executive Summary
Biosite is developing a three-biomarker point-of-care test that could help assess sepsis progression. Following the release of preliminary study data for the test, the firm claimed that it is "on track to launch a prospective multicentre clinical study in the second quarter of 2007." The study will form the basis of an US FDA submission, said the San Diego, California company. The test, called the Triage sepsis panel, consists of biomarkers neutrophil gelatinase-associated lipocalcin (NGAL), c-reactive protein (CRP) and macrophage inflammatory protein-3 (MIP-3).
You may also be interested in...
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.